The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 21, 2003
Filed:
Mar. 31, 2000
Jochen G. Salfeld, North Grafton, MA (US);
Deborah J. Allen, London, GB;
Hendricus R. J. M. Hoogenboom, Hasselt, BE;
Zehra Kaymakcalan, Westboro, MA (US);
Boris Labkovsky, Framingham, MA (US);
John A. Mankovich, Andover, MA (US);
Brian T. McGuinness, Cambridge, GB;
Andrew J. Roberts, Cambridge, GB;
Paul Sakorafas, Shrewsbury, MA (US);
David Schoenhaut, Clifton, NJ (US);
Tristan J. Vaughan, Cambridge, GB;
Michael White, Framingham, MA (US);
Alison J. Wilton, Cambridge, GB;
BASF Aktiengesellschaft, Ludwigshafen, DE;
Abstract
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &agr; (hTNF&agr;) are disclosed. These antibodies have high affinity for hTNF&agr; (e.g., K =10 M or less), a slow off rate for hTNF&agr; dissociation (e.g., K =10 sec or less) and neutralize hTNF&agr; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF&agr; and for inhibiting hTNF&agr; activity, e.g., in a human subject suffering from a disorder in which hTNF&agr; activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.